All In Biotech

Drug Trial Radar · NCT05210868

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Last checked: Nov 19, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

184

Planned (sponsor's estimate)

Start

Nov 16, 2021

Primary completion

Dec 28, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL

Conditions

  • Hematoma

Interventions

  • CM355Drug

    1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the "3+3" dose escalation scheme 2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLT)Time frame: Up to 2 year
  2. Recommended phase II dose (RP2D) and/or (maximum tolerated dose) MTDTime frame: Up to 2 year
  3. Objective response rate(ORR)Time frame: through study completion,an average of 5 year
  4. The safety and tolerability of CM355Time frame: through study completion,an average of 5 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing university cancer hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.